TrialNature medicine2023

Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial.

Stephen A Harrison et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.